头颈癌手术切除患者肌肉减少症与死亡率的相关性
该回顾性病历回顾研究纳入了260例接受头颈部大手术并在术前45天内完成腹部横断面影像检查的头颈癌患者,于L3椎体水平测量肌肉面积。肌肉减少症患者144例(55.4%)。2年总生存率肌肉减少症组为71.9%(n=82),非肌肉减少症组为88.5%(n=85),OR 0.33(95%CI 0.16-0.70);5年总生存率肌肉减少症组为36.5%(n=23),非肌肉减少症组为60.5%(n=26),OR 0.38(95%CI 0.17-0.84)。多因素分析显示肌肉减少症是2年和5年总生存率的显著负向预测因素。
要点
- 头颈癌大手术患者中肌肉减少症发生率为55.4%(144/260)。
- 肌肉减少症组2年总生存率71.9%,非肌肉减少症组88.5%,OR 0.33(95%CI 0.16-0.70)。
- 肌肉减少症组5年总生存率36.5%,非肌肉减少症组60.5%,OR 0.38(95%CI 0.17-0.84)。
核心结论
- 肌肉减少症似乎是接受头颈部大手术的头颈癌患者长期总生存率的显著负向预测因素。
- 肌肉减少症可通过横断面影像准确评估,可能作为临床预后变量和干预领域以改善治疗结局。
研究设计与样本
- 回顾性病历回顾研究,在一家三级学术医院进行。
- 纳入260例接受头颈部大手术切除术且在术前45天内完成腹部横断面影像检查的患者。
- 研究时间为2005年1月1日至2016年12月31日,数据分析时间为2018年6月1日至2019年2月28日。
- 干预措施为在L3椎体水平测量横断面肌肉面积。
主要发现
- 260例患者中男性193例(74.2%),平均(SD)年龄61.1(11)岁。
- 肌肉减少症患者144例(55.4%)。
- 2年总生存率肌肉减少症组为71.9%(n=82),非肌肉减少症组为88.5%(n=85),OR 0.33(95%CI 0.16-0.70)。
- 5年总生存率肌肉减少症组为36.5%(n=23),非肌肉减少症组为60.5%(n=26),OR 0.38(95%CI 0.17-0.84)。
- 多因素分析中,肌肉减少症是2年(OR 0.33,95%CI 0.14-0.77)和5年(OR 0.38,95%CI 0.17-0.84)总生存率的显著负向预测因素。
临床怎么用
- 原文未据此给出推荐。
- 作者认为肌肉减少症可能作为临床预后变量和干预领域以改善治疗结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sarcopenia, or the loss of muscle mass, is associated with poor treatment outcomes in a variety of surgical fields. However, the association between sarcopenia and long-term survival in a broad cohort of patients with head and neck cancer (HNC) is unknown. OBJECTIVE: To determine whether sarcopenia is associated with long-term survival in patients undergoing major head and neck surgery for HNC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective medical records review was conducted at a tertiary care academic hospital. Two hundred sixty patients undergoing major head and neck ablative procedures with cross-sectional abdominal imaging performed within 45 days prior to surgery were included in the analysis. The study was conducted from January 1, 2005, to December 31, 2016. Data analysis was performed from June 1, 2018, to February 28, 2019. INTERVENTIONS: Measurement of cross-sectional muscle area at the L3 vertebra level. MAIN OUTCOMES AND MEASURES: Two- and 5-year overall survival were the primary outcomes. RESULTS: Of the 260 patients included in the study, 193 were men (74.2%); mean (SD) age was 61.1 (11) years. Sarcopenia was present in 144 patients (55.4%). Two-year overall survival was 71.9% of the patients (n = 82) in the sarcopenia group compared with 88.5% of the patients (n = 85) in the nonsarcopenia group (odds ratio [OR], 0.33; 95% CI, 0.16-0.70). At 5 years, overall survival was 36.5% in patients (n = 23) with sarcopenia and 60.5% in patients (n = 26) without sarcopenia (OR, 0.38; 95% CI, 0.17-0.84). On multivariate analysis, sarcopenia was a significant negative predictor of both 2-year (OR, 0.33; 95% CI, 0.14-0.77) and 5-year (OR, 0.38; 95% CI, 0.17-0.84) overall survival. CONCLUSIONS AND RELEVANCE: Sarcopenia appears to be a significant negative predictor of long-term overall survival in patients with HNC undergoing major head and neck surgery. Sarcopenia may be accurately assessed on cross-sectional imaging and may be useful clinically as a prognostic variable and as an area for intervention to improve treatment outcomes.
引用
- Stone L, Olson B, Mowery A, et al. Association Between Sarcopenia and Mortality in Patients Undergoing Surgical Excision of Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31169874. doi:10.1001/jamaoto.2019.1185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。